Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Not Applicable
Deal Type : Not Applicable
Poseida Reports Positive Interim Results For CAR-T Therapy in Myeloma
Details : P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Brand Name : P-BCMA-ALLO1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 27, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Not Applicable
Deal Type : Not Applicable
Poseida Wins RMAT Designation from FDA for Multiple Myeloma Therapy P-BCMA-ALLO1
Details : P-BCMA-ALLO1 is a RMAT designated novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen for the treatment of relapsed/refractory multiple myeloma.
Brand Name : P-BCMA-ALLO1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 16, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Not Applicable
Deal Type : Not Applicable
Poseida Receives FDA Orphan Drug Designation for P-BCMA-ALLO1 in Multiple Myeloma
Details : P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Brand Name : P-BCMA-ALLO1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 13, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : P-MUC1C-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Astellas Pharma
Deal Size : $50.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Astellas gains a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs, P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Brand Name : P-MUC1C-ALLO1
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 07, 2023
Lead Product(s) : P-MUC1C-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Astellas Pharma
Deal Size : $50.0 million
Deal Type : Licensing Agreement
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Details : BPX-601 incorporates high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA). It is being discontinued following the company’s assessment of BPX-601 risk/benefit profile in combinati...
Brand Name : BPX-601
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 14, 2023
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BPX-601 is our first clinical candidate incorporating our high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA).
Brand Name : BPX-601
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 19, 2023
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $6,220.0 million
Deal Type : Collaboration
Details : Under the agreement with Poseida, Roche to develop allogeneic CAR-T cell therapies for hematologic malignancies, including P-BCMA-ALLO1, an allogeneic CAR-T cell product to treat multiple myeloma, and P-CD19CD20-ALLO1 to treat B cell malignancies.
Brand Name : P-BCMA-ALLO1
Molecule Type : Cell and Gene therapy
Upfront Cash : $110.0 million
August 03, 2022
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $6,220.0 million
Deal Type : Collaboration
Details : The Phase 1 trial is an open label, multi-center, 3+3 dose-escalating study designed to assess the safety of P-PSMA-101 in up to 60 adult subjects with mCRPC. The primary objectives of this study are to determine the safety, efficacy, and maximum tolerat...
Brand Name : P-PSMA-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 17, 2022
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : MTS Securities
Deal Size : $35.0 million
Deal Type : Private Placement
Details : Proceeds from the financing will be used to support ongoing clinical development of BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.
Brand Name : BPX-601
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 06, 2021
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : MTS Securities
Deal Size : $35.0 million
Deal Type : Private Placement
Lead Product(s) : Cellular Therapy,Inducible Caspase-9,Rimiducid
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
Details : Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9, an enzyme that is part of the ap...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $5.0 million
September 01, 2021
Lead Product(s) : Cellular Therapy,Inducible Caspase-9,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?